Tarra Shingler

Inspiring, results-oriented and proven life sciences leader with over twenty three years of extensive and diverse drug development, CRO and technology sales spanning pharmaceutical, biotech, medical device and third party vendors excelling in communication, negotiation, and problem solving to achieve sales targets and business growth. A proven self-starter, team player, coach and mentor with excellent verbal and written communication skills, in combination with focused interpersonal, organizational, and problem-solving skills known for high productivity skilled in strategic planning, customer relationship management and team leadership. Demonstrates the ability to interface at all levels within a cross functional organization, establish relationships and build trust with internal and external stakeholders. Received corporate recognition awards for outstanding performance, dynamism and special achievements (2005), Executive Leadership Committee (2012), Process Excellence Advocacy Program (2013), CEO mentoring program (2015), Yellow Belt DCT Technology Implementation (2023) and Healthcare Business Association (HBA) Luminary (2024).

• SalesForce Life Sciences Dreamin quarterly event speaker 2023/2024
• StudyKIK Bee Simple APP Poster Presentation CNS Summit November 2022
• Routine Keynote and Panel Speaker 2022/2023/2024: SCOPE, SCRS Global, ACRP
• Propel Study Start Up by Leveraging Technology to Improve Speed and Quality in Site Contracting & Activation” Presenting April 2013 at IIR’s Partnerships in Clinical Trials.
• Conducting effective vendor qualification to mitigate the risk of a failed partnership” Presented March 2013 at ARENA International Outsourcing in Clinical Trial East Coast.
• Pain and Spasticity – A meta-analysis on the use of Botulinum Toxin Treatment” Accepted for presentation at The Toxins 2008 Conference in Lake Maggiore, Italy June 2008. Edgar Salazar-Grueso, MD, Tarra Shingler, MS, Yuxin Zhang, PhD, Julie Broadbent, PhD.
• The Effects of Transdermal Methylphenidate with Reference to OROS Methylphenidate in ADHD” and “Behavioral Effects of Metylphenidate Transdermal System in Children with ADHD” Journal of Developmental & Behavioral Pediatrics. 27(5):441-442, October 2006. Frank Lopez, MD, Tarra Shingler, MS and Kristen Heinlein, PharmD.
• Effects of Variable Wear Times on Transdermal Methylphenidate in ADHD” Presented at The American Psych Association Conference in Toronto, ON May 2006. Tim Wilens, MD, Sharon Wigal, MD, Howard Abikoff, MD, Sharon Reinhard, MS, Tarra Shingler, MS.
• ADHD Specific Quality of Life with Mixed Amphetamine Salts Extended Release in Adults with ADHD” – Presented at The American Psych Association Conference in Toronto, ON May 2006 and The US Psychiatric and Mental Health Congress in New Orleans, LA November 2006. Jeanne Landgraf, MA, Tarra Shingler, MS.
• Medication Satisfaction Among Adults with ADHD: Long-Term Results From the Quality-of-Life, Effectiveness, Safety and Tolerability (Qu.E.S.T) Study” - Presented at The American Psych Association Conference in Toronto, ON May 2006 and The US Psychiatric and Mental Health Congress in New Orleans, LA November 2006. Margaret Weiss, MD, PhD, Tarra Shingler, MS.
• SF-36 Quality-of-Life Measurement in Adult ADHD and Response to Treatment with Mixed Amphetamine Salts Extended Release” - Presented at The American Psych Association Conference in Toronto, ON May 2006 and The US Psychiatric and Mental Health Congress in New Orleans, LA November 2006. Declan Quinn, MD, Tarra Shingler, MS.